Debanjana Chatterjee
Stock Analyst at JonesTrading
(4.88)
# 270
Out of 5,116 analysts
270
Total ratings
53.6%
Success rate
28.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Reiterated: Buy | $29 → $27 | $11.35 | +137.89% | 29 | Nov 6, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $17 | $4.18 | +306.70% | 27 | Nov 5, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $130 | $103.86 | +25.17% | 23 | Nov 4, 2026 | |
| CTNM Contineum Therapeutics | Reiterated: Buy | $30 | $9.52 | +215.13% | 18 | Nov 3, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $10 | $0.9578 | +944.06% | 19 | Nov 3, 2026 | |
| AZR Azora Therapeutics | Initiated Coverage: Buy | $14 | $4.00 | +250.00% | 1 | Nov 1, 2026 | |
| EYPT EyePoint | Downgraded: Hold | n/a | $0.36 | - | 32 | Oct 23, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $31 | $9.85 | +214.72% | 20 | Oct 22, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $28 | $14.33 | +95.39% | 23 | Oct 22, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | $25 | $11.88 | +110.44% | 9 | Sep 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $3.51 | +469.80% | 7 | Sep 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.06 | +371.70% | 3 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $65 | $34.39 | +89.01% | 15 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.43 | +558.44% | 4 | Aug 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.00 | +233.33% | 4 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $10.17 | +27.83% | 19 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $3.28 | +1,820.73% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.015 | - | 8 | May 22, 2026 |
Intellia Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $29 → $27
Current: $11.35
Upside: +137.89%
Opus Genetics
Nov 5, 2026
Reiterated: Buy
Price Target: $17
Current: $4.18
Upside: +306.70%
Spyre Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $130
Current: $103.86
Upside: +25.17%
Contineum Therapeutics
Nov 3, 2026
Reiterated: Buy
Price Target: $30
Current: $9.52
Upside: +215.13%
Tvardi Therapeutics
Nov 3, 2026
Reiterated: Buy
Price Target: $10
Current: $0.9578
Upside: +944.06%
Azora Therapeutics
Nov 1, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $4.00
Upside: +250.00%
EyePoint
Oct 23, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.36
Upside: -
Sagimet Biosciences
Oct 22, 2026
Reiterated: Buy
Price Target: $31
Current: $9.85
Upside: +214.72%
Trevi Therapeutics
Oct 22, 2026
Reiterated: Buy
Price Target: $28
Current: $14.33
Upside: +95.39%
AbCellera Biologics
Sep 27, 2026
Reiterated: Buy
Price Target: $25
Current: $11.88
Upside: +110.44%
Sep 27, 2026
Reiterated: Buy
Price Target: $20
Current: $3.51
Upside: +469.80%
Sep 15, 2026
Reiterated: Buy
Price Target: $5
Current: $1.06
Upside: +371.70%
Sep 9, 2026
Reiterated: Buy
Price Target: $52 → $65
Current: $34.39
Upside: +89.01%
Aug 28, 2026
Reiterated: Buy
Price Target: $16
Current: $2.43
Upside: +558.44%
Aug 21, 2026
Reiterated: Buy
Price Target: $10
Current: $3.00
Upside: +233.33%
Aug 12, 2026
Reiterated: Buy
Price Target: $13
Current: $10.17
Upside: +27.83%
Aug 10, 2026
Downgraded: Hold
Price Target: $63
Current: $3.28
Upside: +1,820.73%
May 22, 2026
Rated: Hold
Price Target: n/a
Current: $0.015
Upside: -